Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 582 1199

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

ScamUS1 Jun. 17 at 4:14 PM

$ERNA this scam has again another name. Emexa Therapeutics.

1 · Reply

MGeronimo Jun. 16 at 11:25 PM

$ERNA .16 to $2.39 boom

0 · Reply

TwongStocks Jun. 12 at 8:04 PM

Today's reverse split results. 2 of 3 closed green today: $ERNA 1 for 15 Previous close $0.1585, $2.3775 split-adjusted Today's close $2.37 🔴Down 0.32% $VLCN 1 for 8 Previous close $0.659, $5.272 split-adjusted Today's close $5.79 🟢Up 9.83% $SST 1 for 10 Previous close $0.3802, $3.802 split-adjusted Today's close $4.29 🟢Up 12.84%

0 · Reply

MGeronimo Jun. 12 at 5:46 PM

$ERNA 25 million share insider buy taking a gamble here

0 · Reply

_www_larval_com_ Jun. 12 at 3:37 PM

$ERNA just dropped -8% lower to -4% (~130Kv) a moment ago, follow for more volatility.

0 · Reply

ka1954 Jun. 12 at 2:06 PM

$ERNA what is the new OS count and how much cash they have?

1 · Reply

TA_Kongen Jun. 12 at 1:45 PM

$ERNA $VLCN Candidates for pumps. Like ERNA after that insider PP.

0 · Reply

lecorb Jun. 12 at 12:50 PM

$VLCN $ERNA In R/S

1 · Reply

TwongStocks Jun. 12 at 11:19 AM

Three reverse splits today. Two on NASDAQ and one on the NYSE. Trading resumes at 9:00am ET. NASDAQ: $ERNA 1 for 15. Will reduce outstanding shares from approx 110,418,022 to approx 7,361,201. $VLCN 1 for 8. Will reduce outstanding shares from approx 4.3m to approx 540k. NYSE: $SST 1 for 10. Will reduce Class A shares from approx 75.2m to approx 7.52m. Will reduce Class C shares from approx 18.7m to approx 1.87m.

0 · Reply

I_killed_the_kraken Jun. 12 at 8:17 AM

$ERNA insiders loading huge here... https://www.insiderdashboard.com/search?page=1&query=ERNA

0 · Reply

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

May 28, 2025, 8:30 AM EDT - 20 days ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 14, 2025, 8:30 AM EDT - 4 weeks ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 8, 2025, 8:30 AM EDT - 5 weeks ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 29, 2025, 8:30 AM EDT - 7 weeks ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 2 months ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 3, 2025, 8:55 AM EDT - 2 months ago

Ernexa Therapeutics Closes New Funding Round

Feb 26, 2025, 8:30 AM EST - 3 months ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Jan 14, 2025, 8:30 AM EST - 5 months ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 9, 2025, 7:30 AM EST - 5 months ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Nov 14, 2024, 8:30 AM EST - 7 months ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Oct 30, 2024, 8:30 AM EDT - 8 months ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 17, 2024, 8:00 AM EDT - 8 months ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

May 10, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 8, 2024, 9:31 AM EDT - 1 year ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Feb 20, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Jan 3, 2024, 4:15 PM EST - 1 year ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Dec 20, 2023, 4:15 PM EST - 1 year ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 14, 2023, 6:56 PM EST - 1 year ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Nov 1, 2023, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 5, 2023, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

May 24, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 17, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023, 7:30 AM EDT - 2 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Mar 20, 2023, 4:10 PM EDT - 2 years ago

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Feb 22, 2023, 8:00 AM EST - 2 years ago

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Jan 4, 2023, 8:30 AM EST - 2 years ago

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

Dec 20, 2022, 8:05 AM EST - 2 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics

Nov 1, 2022, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

Oct 18, 2022, 8:30 AM EDT - 2 years ago

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

Oct 17, 2022, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

ScamUS1 Jun. 17 at 4:14 PM

$ERNA this scam has again another name. Emexa Therapeutics.

1 · Reply

MGeronimo Jun. 16 at 11:25 PM

$ERNA .16 to $2.39 boom

0 · Reply

TwongStocks Jun. 12 at 8:04 PM

0 · Reply

MGeronimo Jun. 12 at 5:46 PM

$ERNA 25 million share insider buy taking a gamble here

0 · Reply

_www_larval_com_ Jun. 12 at 3:37 PM

$ERNA just dropped -8% lower to -4% (~130Kv) a moment ago, follow for more volatility.

0 · Reply

ka1954 Jun. 12 at 2:06 PM

$ERNA what is the new OS count and how much cash they have?

1 · Reply

TA_Kongen Jun. 12 at 1:45 PM

$ERNA $VLCN Candidates for pumps. Like ERNA after that insider PP.

0 · Reply

lecorb Jun. 12 at 12:50 PM

$VLCN $ERNA In R/S

1 · Reply

TwongStocks Jun. 12 at 11:19 AM

0 · Reply

I_killed_the_kraken Jun. 12 at 8:17 AM

$ERNA insiders loading huge here... https://www.insiderdashboard.com/search?page=1&query=ERNA

0 · Reply

AlertsAndNews Jun. 12 at 3:11 AM

$ERNA Insider Buys (Form 4) Charles Cherington (10%+) buys 21,241,163 shares @ $0.10 avg "On June 9, 2025, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the reporting person acquired 21,241,163 shares of the Issuer's Common Stock." Also spilts tomorrow morning.

0 · Reply

Rjones95 Jun. 12 at 2:48 AM

$ERNA

0 · Reply

DannyTheBull Jun. 11 at 10:22 PM

$ERNA

0 · Reply

TwongStocks Jun. 11 at 8:50 PM

For Thursday, I am currently tracking three reverse splits. Two on NASDAQ and one on the NYSE. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Thursday morning. NASDAQ: $ERNA 1 for 15. Will reduce outstanding shares from approx 110,418,022 to approx 7,361,201. $VLCN 1 for 8. Will reduce outstanding shares from approx 4.3m to approx 540k. NYSE: $SST 1 for 10. Will reduce Class A shares from approx 75.2m to approx 7.52m. Will reduce Class C shares from approx 18.7m to approx 1.87m.

0 · Reply

KNCourt24 Jun. 11 at 1:16 PM

$ERNA This could pump before the split tomorrow in for a quick lotto play

0 · Reply

TwongStocks Jun. 10 at 8:25 PM

$ERNA NASDAQ Equity Corporate Actions Alert # 2025 - 298 Information Regarding the Reverse Stock Split and CUSIP Number Change for Ernexa Therapeutics Inc (ERNA) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-298 "Ernexa Therapeutics Inc (ERNA) will effect a one-for-fifteen (1-15) reverse split of its Common Stock. The reverse stock split will become effective on Thursday, June 12, 2025. In conjunction with the reverse split, the CUSIP number will change to 114082308."

0 · Reply

StocktwitsNews Jun. 10 at 3:02 PM

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish $ERNA $VXF $VTI https://stocktwits.com/news/equity/markets/ernexa-announces-1-for-15-reverse-stock-split/chl7FQGRbzN

0 · Reply

ScamUS1 Jun. 10 at 2:16 PM

$ERNA RS and dilution is their game. This scam has done nothing else.

0 · Reply

jdlman Jun. 10 at 1:40 PM

$ERNA going well

0 · Reply

TwongStocks Jun. 10 at 1:33 PM

$ERNA 1 for 15 reverse split https://www.globenewswire.com/news-release/2025/06/10/3096816/0/en/Ernexa-Therapeutics-Announces-1-for-15-Reverse-Stock-Split.html ERNA is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025 , under the existing trading symbol “ERNA.” Expected to reduce outstanding shares to approx 7,361,201

0 · Reply

Soulaimane1979 Jun. 5 at 11:34 AM

$ERNA 0.15

0 · Reply

Market Cap	1.43M
Revenue (ttm)	580,000.00
Net Income (ttm)	-44.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,679.31%
Debt to Equity Ratio	0.00

Volume	359,085
Avg Vol	12,707,749
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	48%
Beta	4.47
Analysts	Hold
Price Target	N/A